WO2021222595A3 - Multispecific antibodies targeting cd38 and epcam and uses thereof - Google Patents

Multispecific antibodies targeting cd38 and epcam and uses thereof Download PDF

Info

Publication number
WO2021222595A3
WO2021222595A3 PCT/US2021/029931 US2021029931W WO2021222595A3 WO 2021222595 A3 WO2021222595 A3 WO 2021222595A3 US 2021029931 W US2021029931 W US 2021029931W WO 2021222595 A3 WO2021222595 A3 WO 2021222595A3
Authority
WO
WIPO (PCT)
Prior art keywords
epcam
multispecific antibodies
binding domain
antibodies targeting
multispecific
Prior art date
Application number
PCT/US2021/029931
Other languages
French (fr)
Other versions
WO2021222595A2 (en
Inventor
Xiaocheng Chen
Leonard Post
Lei Shi
Qi FEI
Original Assignee
Virtuoso Binco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virtuoso Binco, Inc. filed Critical Virtuoso Binco, Inc.
Publication of WO2021222595A2 publication Critical patent/WO2021222595A2/en
Publication of WO2021222595A3 publication Critical patent/WO2021222595A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)

Abstract

Disclosed herein are multispecific antibodies comprising a CD38 binding domain and an EpCAM binding domain. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising a multispecific antibody comprising a CD38 binding domain and an EpCAM binding domain.
PCT/US2021/029931 2020-04-30 2021-04-29 Multispecific antibodies targeting cd38 and epcam and uses thereof WO2021222595A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020088213 2020-04-30
CNPCT/CN2020/088213 2020-04-30

Publications (2)

Publication Number Publication Date
WO2021222595A2 WO2021222595A2 (en) 2021-11-04
WO2021222595A3 true WO2021222595A3 (en) 2021-12-09

Family

ID=78332405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/029931 WO2021222595A2 (en) 2020-04-30 2021-04-29 Multispecific antibodies targeting cd38 and epcam and uses thereof

Country Status (1)

Country Link
WO (1) WO2021222595A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214212A2 (en) * 2022-05-06 2023-11-09 Virtuoso Binco, Inc. Compositions and uses of cd38 and icam1 antibodies

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246206A1 (en) * 2005-02-23 2009-10-01 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20090311183A1 (en) * 2008-03-03 2009-12-17 Dyax Corp. Metalloproteinase 12 binding proteins
US20110294984A1 (en) * 1998-04-20 2011-12-01 Roche Glycart Ag Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
WO2012048372A1 (en) * 2010-10-11 2012-04-19 Medsaic Pty Ltd Assay for disease detection
US20140079689A1 (en) * 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US20140271664A1 (en) * 2013-03-14 2014-09-18 Leon F. Garcia-Martinez Therapeutic use of antibodies to hgf
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
US20170349668A1 (en) * 2014-07-31 2017-12-07 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
US20180094079A1 (en) * 2014-03-28 2018-04-05 Xencor, Inc. Bispecific Antibodies That Bind to CD38 and CD3
US20180318417A1 (en) * 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
US20190241661A1 (en) * 2016-06-16 2019-08-08 Hoffmann-La Roche Inc. Assay and method for determining cdc eliciting antibodies

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294984A1 (en) * 1998-04-20 2011-12-01 Roche Glycart Ag Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
US20090246206A1 (en) * 2005-02-23 2009-10-01 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20090311183A1 (en) * 2008-03-03 2009-12-17 Dyax Corp. Metalloproteinase 12 binding proteins
WO2012048372A1 (en) * 2010-10-11 2012-04-19 Medsaic Pty Ltd Assay for disease detection
US20140079689A1 (en) * 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US20140271664A1 (en) * 2013-03-14 2014-09-18 Leon F. Garcia-Martinez Therapeutic use of antibodies to hgf
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
US20180094079A1 (en) * 2014-03-28 2018-04-05 Xencor, Inc. Bispecific Antibodies That Bind to CD38 and CD3
US20170349668A1 (en) * 2014-07-31 2017-12-07 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
US20180318417A1 (en) * 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
US20190241661A1 (en) * 2016-06-16 2019-08-08 Hoffmann-La Roche Inc. Assay and method for determining cdc eliciting antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LU WENZONG, DING ZHE: "Identification of key genes in prostate cancer gene expression profile by bioinformatics ", ANDROLOGIA, BLACKWELL, BERLIN., DE, vol. 51, no. 1, e13169, 1 February 2019 (2019-02-01), DE , pages 1 - 10, XP055879590, ISSN: 0303-4569, DOI: 10.1111/and.13169 *
QU ZHENGXING; GOLDENBERG DAVID M.; CARDILLO THOMAS M.; SHI VICTORIA; HANSEN HANS J.; CHANG CHIEN-HSING: "Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 111, no. 4, 15 February 2008 (2008-02-15), US , pages 2211 - 2219, XP086506749, ISSN: 0006-4971, DOI: 10.1182/blood-2007-08-110072 *

Also Published As

Publication number Publication date
WO2021222595A2 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
EP4374852A3 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
WO2020112687A3 (en) Humanized antibodies against c-kit
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
MX2021009138A (en) Anti-cd228 antibodies and antibody-drug conjugates.
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
AU2014304930B2 (en) Antibody binding sites specific for EGFRvIII
MX349198B (en) Rspo binding agents and uses thereof.
MX2022003517A (en) Anti-pd-l1 antibodies and antibody-drug conjugates.
MX2020009842A (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor.
WO2022132596A3 (en) Tissue-specific antigens for cancer immunotherapy
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
WO2023178289A3 (en) Camptothecin conjugates
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
WO2023031623A3 (en) Synthesis of bicycle toxin conjugates, and intermediates thereof
WO2021222595A3 (en) Multispecific antibodies targeting cd38 and epcam and uses thereof
WO2023018722A3 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
MX2022014224A (en) Sars-cov2 neutralizing single domain antibody constructs.
MX2023015469A (en) Methods and compositions for stimulating immune activity.
MX2023014069A (en) Compositions and methods for the treatment of prostate cancer.
MX2023001143A (en) Anti-cd228 antibodies and antibody-drug conjugates.
MX2023013726A (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
WO2021226163A3 (en) Antibodies targeting clec12a and use thereof
WO2021216667A3 (en) Antibodies to chitinase 3-like-1 and methods of use therefor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21796305

Country of ref document: EP

Kind code of ref document: A2